ArticleJournal of Alzheimer's disease reports2018
No Relationship of Anti-Androgens to Alzheimer's Disease or Cognitive Disorder in the MedWatch Database.
Article in Journal of Alzheimer's disease reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Gonadal hormones contribute to sex differences in behavior, pathology and epigenetic modifications in the 3×Tg-AD mouse model of Alzheimer's disease.Biology of sex differences · 2025Article
- Targeting FSH for osteoporosis, obesity, and Alzheimer's disease.Trends in molecular medicine · 2025Review
- Observational
- Drugs associated with a risk of supraventricular tachycardia: analysis using the OpenVigil database.The Journal of international medical research · 2024Article
- Endocrine Dyscrasia in the Etiology and Therapy of Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2024Review
- Androgen Deprivation Therapy for Prostate Cancer: Focus on Cognitive Function and Mood.Medicina (Kaunas, Lithuania) · 2023Review
- Consideration of sex and gender in Alzheimer's disease and related disorders from a global perspective.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Article
- Review
- Androgen deprivation therapy and risk of cognitive dysfunction in men with prostate cancer: is there a possible link?Prostate international · 2022Review
- How Does Androgen Deprivation Therapy Affect Mental Health including Cognitive Dysfunction in Patients with Prostate Cancer?The world journal of men's health · 2021Review
- Alzheimer Gene BIN1 may Simultaneously Influence Dementia Risk and Androgen Deprivation Therapy Dosage in Prostate Cancer.American journal of clinical oncology · 2020Article
- Androgen Deprivation Therapy and Cognitive Function in Prostate Cancer.Current oncology reports · 2020Review
- Editorial Comment.The Journal of urology · 2018Article
- Co-occurrent Alterations of Alzheimer's Genes and Prostate Cancer Genes in Prostate Cancer.Cancer genomics & proteomicsArticle
- Prostate Cancer, Use of Androgen Deprivation Therapy, and Cognitive Impairment: A Population-based Study.Alzheimer disease and associated disordersArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTwo large studies suggest that risk is not increased. But other studies have found increased risk of Alzheimer's disease and impaired cognition.
objectiveTo determine whether androgen deprivation therapy increases the risk of impaired cognition or Alzheimer's disease in men with prostate cancer.
methodsWe used data from MedWatch, the Food and Drug Administration (FDA) Safety Information and Adverse Event Reporting Program. Machine-readable data from MedWatch, including adverse drug reaction reports from manufacturers, are part of a public database. We used the online tool OpenVigil 2.1 to query the database. OpenVigil calculates proportional reporting ratios (PRRs) from adverse drug reaction reports to determine whether the combination of drug and adverse event are related. For example, PRR = 2 indicates that the adverse reaction is two times more frequent in users of the drug than in the general population.
resultsWe analyzed adverse event reporting data for these androgen-deprivation drugs: The luteinizing hormone releasing hormone (LHRH) agonists leuprolide, goserelin triptorelin, histrelin; the anti-androgens flutamide, nilutamide, enzalutamide, and bicalutamide; the LHRH antagonist degarelix; the CYP17 inhibitor abiraterone; the anti-fungal ketoconazole, which is also an anti-androgen administered to men with advanced prostate cancer.
conclusionOur analysis of FDA MedWatch adverse event data reports does not support the idea that androgen deprivation therapy
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.